PROMPT:

Plan of Treatment:  Follow-up in 3 months

RESPONSE (Sentence ending after 60th word):

Interim Phase:  A single-blind crossover study lasting 30 days in the active group. Follow-up in 3 years in the drug group  Long-term Phase:  Follow-up after 3-years in the drug group and 12 years after randomization in the active drug group  Data to support the Phase 4 Dose Escalation:  In the active drug group, 2 uncontrolled studies found no significant difference between study arms for safety or effectiveness at the time of discontinuation, whereas 2 uncontrolled studies found significant differences between study arms. 